Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 3,919 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prostate Cancer Clear all

Conditions: Prostate Cancer
Interventions: perillyl alcohol; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 120 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 8
States / cities: Freeport, Illinois • Green Bay, Wisconsin • Janesville, Wisconsin + 4 more

Conditions: Malignant Neoplasm of Prostate
Interventions: Da Vinci ® Xi system - MP Robotic Radical Prostatectomy, Da Vinci ® SP system - SP Robotic Radical Prostatectomy; Device
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 19 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma, Small Cell Lung Carcinoma, Prostate Cancer, Pancreas Cancer
Interventions: Talazoparib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 14
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 4 more

Conditions: Prostate Cancer
Interventions: pomegranate liquid extract; Dietary Supplement
Lead sponsor: Roll International Corporation; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Bladder Cancer, Prostate Cancer (Adenocarcinoma), Endometrial Cancer, Hypertension, Hyperlipidemia (E.G., Hypercholesterolemia), Diabetes Mellitus
Interventions: PC2: Primary Care Connect; Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions: LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride; Drug · Radiation
Lead sponsor: Ajjai Alva, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more

Conditions: Prostate Cancer, Biochemically Recurrent
Interventions: 18F-DCFpyL; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Metastatic Castrate Resistant Prostate Cancer
Interventions: TRC105; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions: sunitinib malate, docetaxel, prednisone; Drug
Lead sponsor: John P. Fruehauf; Other
Eligibility: 18 Years and older · Male only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Orange, California

Conditions: Prostatic Neoplasms
Interventions: CNTO 328, Docetaxel; Drug
Lead sponsor: Centocor, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more

Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Colorectal Cancer, Head and Neck Cancer
Interventions: GI-6207 [Recombinant Saccharomyces Cerevisia, (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)]); Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Invitae multi-cancer gene panel; Diagnostic Test
Lead sponsor: Invitae Corporation; Industry
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 19
States / cities: San Diego, California • San Francisco, California • Lakewood, Colorado + 13 more

Conditions: Neoplasms
Interventions: VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg; Drug
Lead sponsor: Vincerx Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 13
States / cities: Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: recombinant fowlpox-prostate specific antigen vaccine, recombinant vaccinia prostate-specific antigen vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Elevated PSA, Prostate Cancer
Interventions: Targeted biopsy; Device
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: Male only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Localized Prostate Cancer
Interventions: Robotic Waterjet Treatment; Device
Lead sponsor: PROCEPT BioRobotics; Industry
Eligibility: 40 Years and older · Male only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 3
States / cities: Los Angeles, California • Glenview, Illinois • New York, New York

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v7, Metastatic Malignant Neoplasm in the Bone
Interventions: Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Sirolimus; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer, MSI-H/dMMR Gastroesophageal-junction Cancer, Endometrial Cancer, Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions: EIK1005, pembrolizumab (KEYTRUDA® ); Drug
Lead sponsor: Eikon Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Doral, Florida • Hialeah, Florida + 7 more

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: enzalutamide, bicalutamide, orchiectomy, leuprolide acetate, goserelin acetate, laboratory biomarker analysis; Drug · Procedure · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 4
States / cities: Birmingham, Alabama • Detroit, Michigan • Columbus, Ohio

Conditions: Advanced Solid Tumor
Interventions: M9466, Tuvusertib, Abiraterone acetate, Prednisone/Prednisolone; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New York, New York • Houston, Texas

Conditions: Prostate Cancer
Interventions: Fermented Soy, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: New Haven, Connecticut • New London, Connecticut • Wakefield, Rhode Island

Conditions: Metastatic Prostate Cancer
Interventions: sipuleucel-T, enzalutamide; Biological · Drug
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 19
States / cities: Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more

Conditions: Prostate Cancer
Interventions: Tissue Elastography Imaging; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hormone-Resistant Prostate Cancer, Metastatic Malignant Neoplasm in the Bone, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Fluorine F 18 Sodium Fluoride; Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 4
States / cities: Boston, Massachusetts • Durham, North Carolina • Portland, Oregon + 1 more

Search by objective public record fields.

Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy

Single-Port Versus Multi-Port Robotic Radical Prostatectomy

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Open-label Extension Study of the Effects of Pomegranate Extract on Rising PSA After Primary Therapy for Prostate Cancer

Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...

PROCLAIM: Germline Genetic Testing for Prostate Cancer Patients

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer

PRCT002 PRostate Cancer Treatment With the AQUABEAM Robotic System

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

Nutrition and Prostate Cancer

A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer

Evaluation Ultrasound Elasticity/Tissue Strain-Hardening Imaging for Prostate Cancer Patients Undergoing Radical Prostatectomy

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases